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I. INTRODUCTION 
Type 1 Diabetes Mellitus (T1D) is a chronic condition characterized by inadequate 
insulin production in the body as a result of the autoimmune destruction of insulin-producing 
pancreatic beta cells. Insulin is the hormone critical for the uptake and metabolism of glucose 
by liver, muscle, and cardiac cells.1 Consequently, glucose uptake and metabolism is 
impaired in individuals with T1D; however, normal blood glucose levels can be maintained 
with intensive insulin therapy.2,3 Studies have shown significant increases in prevalence and 
incidence of T1D in youth in the U.S.4,5 Inadequate management of T1D can result in severe, 
acute complications such as diabetic ketoacidosis as well as severe, chronic complications 
that are macrovascular and microvascular in nature.6,7 Thus, self-management of T1D is 
critical for glycemic control and morbidity risk reduction8; however, it is especially 
challenging for youth with T1D to adhere to the meticulous routine necessary for optimal 
glycemic control due to the psychosocial and educational barriers characteristic of 
adolescence.9,10 As a result, glycemic control is frequently poor in adolescents with T1D.11  
The FL3X Clinical Trial was a randomized 18-month efficacy trial (developed and 
piloted by Mayer-Davis, Seid, and Maahs) that employed adaptive behavioral intervention to 
improve glycemic control in adolescents with T1D.12 Participants of the pilot study were 
randomized to the FL3X program or to usual diabetes care within each clinical site. The 
participants were adolescents aged 12-16 years with a T1D diagnosis ≥1 year, literacy in 
English, and a HbA1c between 8–13%. The study occurred over three months and included 
three in-person and two optional sessions. The duration of the sessions was between 40–60 
minutes.33 Following this initial small scale RCT, the pilot was extended into an intervention 
that was fully powered, employed an adaptive clinical intervention, and lasted 18 months for 
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long-term assessment. Inclusion criteria for this intervention were adolescents aged 13-16 
years with a T1D diagnosis ≥1 year, literacy in English, a HbA1c between 8–13% who have 
a primary caregiver willing to participate. The adaptive aspect of the intervention utilized an 
approach in which each participant (randomized into the FL3X program) attends “FL3X 
Basic” for an initial three months followed by assignment to either “FL3X Check-In” or 
“FL3X Regular” depending on A1c measurements at defined intervals. Thus, the FL3X 
intervention tailors treatment to match the progress towards T1D self-management goals of 
each participating adolescent.41The utilization of motivation interviewing (MI), problem-
solving skills training, and Behavioral Family System Therapy, employed in the FL3X 
Intervention, may improve glycemic control as well as related health, behavioral, and 
psychological impacts in adolescents with T1D.13,14 However, to successfully employ the 
methods of the FL3X clinical trial and optimize T1D management in other adolescent 
populations, the clinical intervention must be integrated into T1D care practices.  
An existing T1D-care program in the Greenville Health System (GHS) in Greenville 
South Carolina is the Get Real About Diabetes (GRAD) program, which also employs MI in 
T1D counseling to help adolescents, identified as having poor glycemic control according to 
their providers in GHS, better manage their T1D.15 Due to changes in staffing that temporarily 
interrupted GRAD, the former period of GRAD is referred to as “GRAD 1” (July 1, 2008 – 
June 30, 2011) and the on-going period of GRAD is referred to as “GRAD 2” (June 1, 2013 – 
July 1, 2017) in this study. The GRAD 1 & 2 programs are clinical practices that have 
employed similar, but less structured methods than those of the FL3X intervention, while the 
FL3X intervention is a randomized, well-structured program studying the effectiveness of 
adaptive behavioral counseling in the management of T1D in adolescents.12,15 Therefore, the 
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methods and outcomes of the GRAD 1 & 2 programs may differ significantly in design and 
outcomes from each other and from FL3X. However, as a result of already employing similar 
counseling strategies as FL3X, the GRAD practice is particularly receptive to the integration 
of FL3X. 
 Thus, the goals of this FL3X-GRAD Integration study are to evaluate the initial 
implementation and ongoing practice of GRAD, compare FL3X and GRAD, and determine 
how the FL3X intervention may be feasibly implemented into the GRAD practice, by 
building upon the existing structure of this program in GHS. This integration design project 
will employ the analysis of the methods, outcomes, and provider team experiences of both 
the GRAD 1 and GRAD 2 programs to determine the logistics by which the FL3X protocol 
should be incorporated into GRAD for optimal T1D management and outcomes in 
participants. With the proposed FL3X-GRAD integration model, similar approaches can be 
designed for the clinical integration of FL3X into other practices to optimize the outcomes of 
other populations of adolescents with T1D. 
These objectives will be accomplished by completing the following Specific Aims: 
Aim 1: To analyze the available data from GRAD and the “non-GRAD” control 
group to evaluate the initial implementation and ongoing practice of GRAD (GRAD 1 
& GRAD 2). 
Aim 2: To investigate and compare the FL3X Intervention and the GRAD programs 
to determine key differences in program methods and delivery. 
Aim 3: To identify practical ways to implement the FL3X Intervention, building 
upon the infrastructure of the GRAD program. 
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II. LITERATURE REVIEW 
 
T1D Description 
Type 1 Diabetes (T1D) is a chronic condition characterized by the body’s 
autoimmune destruction of pancreatic beta cells, which are responsible for insulin 
production.1 Insulin is a critical peptide hormone in the regulation of glucose metabolism. 
Upon binding to insulin cell-surface receptors, insulin activates a signaling pathway that 
results in the recruitment of glucose transporter 4 (GLUT4) to the cellular membranes of 
liver, muscle, and cardiac cells, increasing the rate of glucose uptake by these cells.2 Other 
insulin signaling pathways stimulate the catabolic pathways of glucose metabolism to 
produce energy from intracellular glucose.3 In cases of T1D, the inadequate insulin secretion 
by pancreatic beta cells results in the lack of activation of the signaling pathways involved in 
glucose uptake and catabolism by cells. Consequently, serum glucose levels remain elevated 
(hyperglycemia), and low levels of intracellular glucose are available to produce energy in 
GLUT4-dependent cells. 
 
T1D Prevalence & Incidence Amongst Youth in the US 
The SEARCH for Diabetes in Youth Study conducted an assessment of the 
prevalence of T1D amongst youth less than 20 years of age across five areas in the United 
States, between 2001-2009. The estimated change in prevalence was determined by 
comparing data collected in 2001 and 2009. The prevalence of T1D in the study population 
increased from 1.48 per 1000 (95% CI, 1.44-1.52) in 2001 to 1.93 per 1000 in 2009 (95% CI, 
1.88-1.97). Thus, there was a statistically-significant increase of 30% (95% CI, 25.4%-
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34.9%) in T1D prevalence amongst the youth in the eight-year study. Further analysis 
elucidated that the greatest increase in T1D prevalence occurred with youth between 15-19 
years of age. The demographics of the study population was found to be generalizable to that 
of the US, suggesting that the increase in prevalence of T1D found in the study represents 
T1D prevalence trends amongst youth in the US.4 
Data from the SEARCH study was also analyzed to examine trends in the incidence 
of T1D amongst youth in the US as well. A significant increase from 19.5 cases per 100,000 
youths per year in 2002-2003 to 21.7 cases per 100,000 youths per year in 2011–2012 was 
observed in the study population, indicating a significant 1.4% annual rise in incidence. 
Further subgroup analysis determined that the increase in T1D incidence was significantly 
higher for Hispanic youth than non-Hispanic, white youth.5 
 
Complications associated with T1D 
Long-term complications associated with hyperglycemia can be classified as 
macrovascular or microvascular in nature. Macrovascular complications include coronary 
artery disease, peripheral arterial disease, and stroke primarily from the narrowing of arterial 
walls (atherosclerosis).42 The risk of developing cardiovascular complications is ten-times 
higher for individuals with T1D than non-diabetic individuals. Furthermore, the likelihood of 
a negative outcome following an acute coronary event is greater for patients with T1D than 
non-diabetic patients.  
Individuals with T1D are also at increased risk for microvascular conditions.1 
Microvascular complications include diabetic nephropathy, neuropathy, and retinopathy. The 
most frequent microvascular complication is diabetic retinopathy, which is the cause of 
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approximately 10,000 incident cases of blindness every year in the United States. In addition, 
diabetic nephropathy is most common cause of kidney failure in the United States and is 
preceded by the progression of microalbuminuria to proteinurea that occurs in diabetic 
patient without treatment. The duration and severity of the hyperglycemia correlates with the 
risk of developing the aforementioned microvascular complications with T1D.42 
 In the short-term, T1D-related complications may result from hypoglycemia or 
hyperglycemia. Hypoglycemia is a consequence of excessive insulin intake and/or 
inadequate consumption of carbohydrate. Complications associated with hypoglycemia 
include “tremor, palpitations, agitation, weakness, confusion and seizures”. If left untreated, 
hypoglycemia may result in brain damage and death.6 Conversely, hyperglycemia is a 
consequence of inadequate insulin intake and/or excessive consumption of carbohydrate. 
Complications associated with hyperglycemia include: diuresis, vomiting, hyperventilation, 
diabetic ketoacidosis (DKA), coma, and death.7 The Search for Diabetes in Youth Study 
found that 29.4% of adolescents diagnosed with T1D present with DKA, which has the 
potential to be fatal. The significant prevalence of life-threatening DKA amongst US youth 
with T1D suggests the need for efforts to prevent this severe, acute complication in this 
population.17  
 
T1D Management 
The Diabetes Control and Complications Trial conducted between 1983-1989 
demonstrated that intensive insulin therapy (IIT) greatly improved glycemic control and 
reduced development and progression of T1D related complications amongst youth with 
T1D.8 Since then, advancements in insulin quality, glucose monitoring devices, and the 
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administration of insulin via insulin pumps have contributed to the current widespread 
utilization of IIT amongst individuals with T1D. However, despite advancements in insulin 
administration technology, individuals with T1D must consistently monitor the content and 
amount of food consumed and calculate the appropriate carbohydrate ratio or correction 
factor, given the time of day, to accurately bolus insulin. Thus, the management of T1D in 
adolescents is intensive and requires daily self-management and support from parents, peers, 
and school staff in addition to health professionals to maintain glycemic control.18 
Every year, the American Diabetes Associations (ADA) sets standards of care to 
promote optimal T1D management and outcomes in affected individuals. For children and 
adolescents with T1D, the ADA emphasizes the consideration of unique aspects of T1D care 
and management, including “changes in insulin sensitivity related to physical growth and 
sexual maturation, ability to provide self-care, supervision in the child care and school 
environment, and neurological vulnerability to hypoglycemia and hyperglycemia in young 
children, as well as possible adverse neurocognitive effects of diabetic ketoacidosis”.30 Thus, 
to address these aspects of T1D care in children and adolescents, the ADA advocates for a 
multidisciplinary provider team trained in the “educational, nutritional, behavioral, and 
emotional needs of the growing child and family” to provide self-management education and 
support, medical nutrition education, and psychosocial support upon diagnosis and 
subsequently in a manner that builds on prior knowledge for patients with T1D. The 
following table contains the comprehensive standards of medical care, set by the ADA in 
2018, for adolescents with T1D:30 
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Aspect of T1D 
Care/Complications 
Diabetes Self-
management Education 
and Support 
 
Psychosocial Issues 
 
Glycemic Control 
 
Thyroid Disease 
 
Celiac Disease 
 
Recommendations 
• Youth with type 1 
diabetes and 
parents/caregivers 
(for patients aged 18 
years) should receive 
culturally sensitive 
and developmentally 
appropriate 
individualized 
diabetes self-
management 
education and support 
according to national 
standards at diagnosis 
and routinely 
thereafter.  
 
• At diagnosis and during routine 
follow-up care, assess 
psychosocial issues and family 
stresses that could impact 
adherence to diabetes 
management and provide 
appropriate referrals to trained 
mental health professionals, 
preferably experienced in 
childhood diabetes. 
• Mental health professionals 
should be considered integral 
members of the pediatric 
diabetes multidisciplinary team.  
• Encourage developmentally 
appropriate family involvement 
in diabetes management tasks 
for children and adolescents, 
recognizing that premature 
transfer of diabetes care to the 
child can result in 
nonadherence and deterioration 
in glycemic control. 
• Providers should consider 
asking youth and their parents 
about social adjustment (peer 
relationships) and school 
performance to determine 
whether further intervention is 
needed. B Assess youth with 
diabetes for psychosocial and 
diabetes-related distress, 
generally starting at 7–8 years 
of age.   
• At diagnosis and during routine 
follow-up care, consider 
assessing psychosocial issues 
and family stresses that could 
impact diabetes management 
and provide appropriate 
referrals to trained mental 
health professionals, preferably 
experienced in childhood 
diabetes.  
• Offer adolescents time by 
themselves with their care 
provider(s) starting at age 12 
years, or when developmentally 
appropriate. E Starting at 
puberty, preconception 
counseling should be 
incorporated into routine 
diabetes care for all girls of 
childbearing potential.   
• The majority of 
children and 
adolescents with type 
1 diabetes should be 
treated with intensive 
insulin regimens, 
either via multiple 
daily injections or 
continuous 
subcutaneous insulin 
infusion. 
• All children and 
adolescents with type 
1 diabetes should self-
monitor blood 
glucose levels 
multiple times daily, 
including premeal, 
prebedtime, and as 
needed for safety in 
specific clinical 
situations such as 
exercise, driving, or 
for symptoms of 
hypoglycemia. 
• Continuous glucose 
monitoring should be 
considered in children 
and adolescents with 
type 1 diabetes, 
whether using 
injections or 
continuous 
subcutaneous insulin 
infusion, as an 
additional tool to help 
improve glycemic 
control. Benefits of 
continuous glucose 
monitoring correlate 
with adherence to 
ongoing use of the 
device. 
• Automated insulin 
delivery systems 
improve glycemic 
control and reduce 
hypoglycemia in 
adolescents and 
should be considered 
in adolescents with 
type 1 diabetes. 
• An A1C goal of 
<7.5% (58 
mmol/mol) is 
recommended across 
all pediatric age-
groups.  
 
• Consider testing 
individuals with 
type 1 diabetes for 
antithyroid 
peroxidase and 
antithyroglobulin 
antibodies soon 
after the diagnosis. 
• Measure thyroid-
stimulating 
hormone 
concentrations soon 
after the diagnosis 
of type 1 diabetes 
and after glucose 
control has been 
established. If 
normal, consider 
rechecking every 1–
2 years or sooner if 
the patient develops 
symptoms 
suggestive of 
thyroid 
dysfunction, 
thyromegaly, an 
abnormal growth 
rate, or an 
unexplained 
glycemic variation. 
 
• Screen individuals with 
type 1 diabetes for celiac 
disease soon after the 
diagnosis of diabetes by 
measuring IgA tissue 
transglutaminase 
antibodies, with 
documentation of normal 
total serum IgA levels or, 
if IgA deficient, IgG tissue 
transglutamine and 
deamidated gliadin 
antibodies.  
• Repeat screening within 2 
years of diabetes diagnosis 
and then again after 5 
years and consider more 
frequent screening in 
children who have 
symptoms or a first-degree 
relative with celiac 
disease.  
• Individuals with biopsy-
confirmed celiac disease 
should be placed on a 
gluten-free diet and have a 
consultation with a 
dietitian experienced in 
managing both diabetes 
and celiac disease. 
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Aspect of T1D Care Hypertension 
 
Dyslipidemia 
 
 
Smoking 
 
 
Diabetic Kidney 
Disease  
 
Retinopathy 
 
 
Neuropathy 
 
Recommendations 
Screening  
• Blood pressure should 
be measured at each 
routine visit. Children 
found to have high-
normal blood pressure 
(systolic blood 
pressure or diastolic 
blood pressure $90th 
percentile for age, sex, 
and height) or 
hypertension (systolic 
blood pressure or 
diastolic blood 
pressure $95th 
percentile for age, sex, 
and height) should 
have elevated blood 
pressure con- firmed 
on 3 separate days. 
 
Treatment  
• Initial treatment of 
high-normal blood 
pressure (systolic 
blood pressure or 
diastolic blood 
pressure consistently 
$90th percentile for age, 
sex, and height) 
includes dietary 
modification and 
increased exercise, if 
appropriate, aimed at 
weight control. If 
target blood pressure is 
not reached within 3–6 
months of initiating 
lifestyle intervention, 
pharmacologic 
treatment should be 
considered.  
• In addition to lifestyle 
modification, 
pharmacologic 
treatment of 
hypertension (systolic 
blood pressure or 
diastolic blood 
pressure consistently 
$95th percentile for age, 
sex, and height) should 
be considered as soon 
as hypertension is 
confirmed.  
• ACE inhibitors or 
angiotensin receptor 
blockers should be 
considered for the 
initial pharmacologic 
treatment of 
hypertension, 
following reproductive 
counseling and 
implementation of 
effective birth control 
due to the potential 
teratogenic effects of 
both drug classes. 
• The goal of treatment 
is blood pressure 
consistently <90thh 
percentile for age, sex, 
and height.  
 
Testing   
• Obtain a fasting lipid 
profile in children ≥10 
years of age soon after the 
diagnosis (after glucose 
control has been 
established).  
• If lipids are abnormal, 
annual monitoring is 
reasonable. If LDL 
cholesterol values are 
within the accepted risk 
level (,100 mg/dL [2.6 
mmol/L]), a lipid profile 
repeated every 3–5 years is 
reasonable.  
 
Treatment 
• Initial therapy should 
consist of optimizing 
glucose control and 
medical nutrition therapy 
using a Step 2 American 
Heart Association diet to 
decrease the amount of 
saturated fat in the diet. 
• After the age of 10 years, 
addition of a statin is 
suggested in patients who, 
despite medical nutrition 
therapy and lifestyle 
changes, continue to have 
LDL cholesterol >160 
mg/dL (4.1 mmol/L) or 
LDL cholesterol >130 
mg/dL (3.4 mmol/L) and 
one or more cardiovascular 
disease risk factors, 
following reproductive 
counseling and 
implementation of 
effective birth control due 
to the potential teratogenic 
effects of statins. 
• The goal of therapy is an 
LDL cholesterol value 
<100 mg/dL (2.6 mmol/L).  
 
• Elicit a smoking 
history at initial 
and follow-up 
diabetes visits. 
Discourage 
smoking in youth 
who do not 
smoke and 
encourage 
smoking 
cessation in those 
who do smoke. 
 
Screening  
• Annual screening 
for albuminuria 
with a random 
spot urine sample 
for albumin-to-
creatinine ratio 
should be 
performed at 
puberty or at age 
≥10 years, 
whichever is 
earlier, once the 
child has had 
diabetes for 5 
years.   
 
Treatment 
• When 
persistently 
elevated urinary 
albumin-to-
creatinine ratio 
(>30 mg/g) is 
documented with 
at least two of 
three urine 
samples, 
treatment with an 
ACE inhibitor 
should be 
considered and 
the dose titrated 
to maintain blood 
pressure within 
the age-
appropriate 
normal range. 
The urine 
samples should 
be obtained over 
a 6-month 
interval following 
efforts to 
improve 
glycemic control 
and normalize 
blood pressure. 
 
 
• An initial 
dilated and 
comprehensive 
eye 
examination is 
recommended 
once youth have 
had type 1 
diabetes for 3–5 
years, provided 
they are age 
≥10 years or 
puberty has 
started, 
whichever is 
earlier.  
• After the initial 
examination, 
annual routine 
follow-up is 
generally 
recommended. 
Less-frequent 
examinations, 
every 2 years, 
may be 
acceptable on 
the advice of an 
eye care 
professional 
and based on 
risk factor 
assessment. E 
• Consider an 
annual 
comprehensi
ve foot exam 
for the child 
at the start of 
puberty or at 
age ≥10 
years, 
whichever is 
earlier, once 
the youth 
has had type 
1 diabetes 
for 5 years. 
 
Figure 1: 2018 ADA recommendations for standards of medical care of children/adolescents with T1D.30 
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T1D Insulin Regimens  
Several insulin therapies exist for patients with T1D. One therapy is MDI (Multiple 
Daily Injections), in which the patient receives a basal-insulin injection of long- or 
intermediate-acting insulin analogs that is supplemented with bolus injections of rapid-acting 
insulin analogs around mealtime glucose intake. Another therapy is continuous subcutaneous 
insulin infusion (CSII) via insulin pumps, which deliver a 24-hour preselected adjustable 
basal rate of insulin along with patient-activated mealtime bolus doses, eliminating the need 
for periodic insulin injections.34 A meta-analysis of randomized control trials (RCT) 
comparing the efficacies of MDI and CSII found CSII to be more effective in lowering 
HbA1c in children with T1D.35 Furthermore, three of the RCTs monitored total insulin dose 
and found that significantly lower insulin was utilized in the CSII groups than the MDI 
groups.36, 37, 38 One of the two RCTs that collected BMI results found significantly lower BMI 
SDS in patients treated with CSII than patients treated with CSII.38, 39 Finally, the meta-analysis 
found that patients receiving CSII had less episodes of DKA and severe hypoglycemic 
complications and reported higher quality of life than patients receiving MDI.35  
MDI and CSII therapy can be augmented with continuous glucose monitoring 
(CGM), a technology that warns patients of imminent hyper- or hypoglycemia based on 
trending blood glucose levels. From this alert, the patient or the insulin pump may alter or 
cease insulin delivery.34 The DIAMOND randomized clinical trial, which compared the 
efficacy of CGM augmented MDI versus usual MDI in adults with T1D, found a greater 
decrease in HbA1c in the CGM group. Additionally, the mean duration of hypoglycemia per 
day was significantly lower in the CGM+MDI group (43 min/d) than the control MDI group 
(80 min/d).45 A COMISAIR Study found patients with T1D using real-time continuous 
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glucose monitoring (as part of a sensor-augmented insulin regimen) combined with MDI or 
CSII to have significantly decreased HbA1c and incidence of hypoglycemia than patients 
using MDI or CSII alone, respectively.46 Furthermore, the STAR 3 study, which compared the 
efficacy of CGM augmented MDI and CGM augmented CSII, found that patients receiving 
CGM augmented CSII had better and safer glycemic control than CGM augmented MDI.40 
A study sample from the SEARCH study was also examined to study the association 
between insulin regimen and change in regimen on clinical outcomes in youth with T1D. 
This study found that individuals who began to follow more intensive (MI) regimens or who 
had no change (NC) in regimen between initial and follow-up visits (mean 36 months) had 
lower baseline A1c and smaller increases in A1c than individuals who had less intensive (LI) 
regimens between the initial and follow-up visits. Likelihood of achieving target A1c was 
also found to be correlated with younger age, CSII, and change to MI. Additionally, the 
likelihood of change to MI or NC was found to be significantly higher in participants who 
were “younger, non-Hispanic white, and from families of higher income and parental 
education and who had private health insurance”.43 
 
T1D Management is Inadequate in many Youth 
A study conducted on 13,316 participants in the T1D Exchange Clinic Registry found 
that only 21% of participants between 13-20 years old with T1D ≥1 year met the HbA1c 
target (<7.5%) set by the American Diabetes Association.11 These data suggest that there are 
contextual challenges for adolescents in maintaining glycemic control. Barriers to T1D self-
management likely relate to the developmental stages, physiological differences related to 
sexual maturity, and changes in family dynamics characteristic of adolescence.47 
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 In addition, results from the SEARCH study indicated a significant decline in 
glycemic control in the six years following T1D diagnosis in adolescents. The analysis found 
that decreasing diabetes-specific quality of life scores, which are indicative of psychosocial 
burdens, were predictors of increases in A1c in the participants.9  
Further analysis of the SEARCH study elucidated that minority youth with T1D were 
significantly more likely to have elevated A1C as compared to non-Hispanic white youth. 
Minority youth were also more likely to have cardiovascular risk factors such as high blood 
pressure, dyslipidemia, elevated apoB and elevated LDL. Furthermore, initial indications of 
arterial stiffness, kidney disease, neuropathy, and retinopathy were especially observed in 
ethnic minority youth with T1D.31 Low socioeconomic status (SES) has also been implicated 
with poor glycemic control. A systematic review conducted on existing literature on youth 
with T1D found that 18 studies reported significantly higher A1c in lower-SES youth than in 
higher-SES youth.32 Having determined minority and lower-SES youth with T1D to be at 
higher risk for poor glycemic control and the related complications, these studies recommend 
efforts to improve T1D care, risk factor screening, and management in these populations.31,32 
 
Barriers to T1D Management in Youth 
 Adolescence is a time of substantial risk for psychological disorders10, and one 
longitudinal study found that adolescents with T1D were 2-3 times more likely to be 
diagnosed with psychiatric disorders in the 10 years following onset compared to adolescents 
that are clinically well.20 Symptoms of these disorders, such as such as depression and 
anxiety, are associated with negative effects on adherence to therapy and glycemic control in 
youth with T1D.21,22 
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 Analysis of the barriers to care reported by the participants’ families in the SEARCH 
study shed light on the perceived limitations in provider communication and education in 
T1D care. 48% of the families of the participants with T1D reported that the information on 
T1D management offered by their providers was inadequate. Furthermore, 43% families of 
the participants with T1D reported a lack of effective communication by their providers. The 
insufficient provider education and communication that is perceived by almost half the 
families of the participants indicate that these areas are significant barriers to adherence to 
T1D management.23 These challenges are supported by another study, which held focus 
groups with children and youth with T1D. Common challenges in T1D management were 
reported, including: recognizing and correcting low blood glucose, constantly monitoring 
blood glucose and administering insulin, and feeling different when interrupting social 
interactions to manage blood glucose. Reflecting on these perspectives, the study emphasized 
the role of the family and provider in reducing the educational and psychosocial barriers to 
T1D management in youth.24  
 
Family Involvement in T1D Management  
 A randomized controlled trial assessing the efficacy of Behavioral Family Systems 
Therapy for Diabetes (BFST-D) for adolescents with suboptimal A1c found significant A1c 
improvement in the BFST-D group in comparison to the standard care (SC) and multifamily 
educational support (ES) groups at 6 and 18 month follow-ups. Further analysis showed that 
a significantly greater proportion of the BFST-D group attained improved T1D treatment 
adherence compared to the SC and ES groups. Thus, this study suggests that BFST-D is 
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significantly tied to improved adherence to T1D diabetes management and improved A1c 
over time in youth with T1D.14  
 
Motivational Interviewing in T1D Provider Care 
 Motivational interviewing (MI) is a collaborative, patient-centered technique used by 
providers to engage the patient’s intrinsic motivation to make behavioral changes.26 Originally 
designed to treat substance abuse, MI has since then been utilized to improve patient 
adherence to therapy for a number of chronic health conditions.13  
 A randomized, controlled study conducted with 66 teenagers with T1D assessed the 
efficacy of motivational interviewing. Following the completion of the study at 12 months, 
the MI intervention group was found to have significantly lower A1c and significantly better 
psychosocial well-being than the control group. Furthermore, the significant difference in 
A1c between the groups was maintained at the 24-month follow-up. Thus, results of the 
study support the power of MI in improving adherence to therapy, and subsequent glycemic 
control in adolescents with T1D.27 
 
The Flexible Lifestyles for Youth (FL3X) Study 
The Flexible Lifestyles for Youth (FL3X) is a behavioral intervention for high-risk 
youth with T1D. Its pilot and feasibility trial randomly assigned participants to FL3X or a 
control group to receive usual care. The FL3X programming included motivational 
interviewing, Bright IDEAS problem-solving, BFST-D, and a “toolbox” of additional 
resources including diabetes education. Motivational interviewing engages the participant 
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with the intervention material, increasing the likelihood of adherence to T1D-problem 
solving goals. The BFST-D approach involves providing instructions, feedback, modeling, 
rehearsal, and individualized behavioral homework regarding parental support of T1D self-
management goals established by the participant to enhance family teamwork and problem-
solving. The toolboxes incorporated content on family communication and teamwork 
activities, T1D education, social support, diet and physical activity, and communication 
technology as recommended by the ADA and ISPAD to enhance T1D-self management of 
participants.41 Analysis of the pilot found high retention and attendance by the participants. 
Additionally, the intervention acceptability was high as 100% of the adolescents and 91% of 
their parents claimed they would encourage FL3X to others. The fidelity of the trained FL3X 
coaches was not consistent as two of the four coaches had moderate, instead of high, 
adherence to the content guidelines of each session. The HbA1c effect size was non-
significant; however, the pilot was not designed for power to detect effect sizes on HbA1c in 
FL3X. Thus, the pilot concluded that FL3X has great potential to improve glycemic 
management by high-risk youth with T1D, and further, long-term study of the FL3X 
intervention is recommended.33 
 
Considerations to Clinical Integration of an Intervention 
Incorporation of a public health service into healthcare practice necessitates that the 
intervention be successfully integrated “across providers, settings of care, conditions, and 
time”.28 Thus, regardless of organizational structure, an optimal clinical integration model 
requires the presence of the following characteristics: agenda alignment, care coordination, 
accountability; physical and electronic infrastructure; program review and performance 
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measurement.28 The proposed model of clinical integration must also address provider time 
and access to training and resource support, funding for resources and hiring, and 
receptiveness to the treatment method and training in order to support and sustain the 
incorporation of the intervention into a clinic’s practice.29 
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ABSTRACT 
 
Self-management of type 1 diabetes mellitus (T1D) is critical in glycemic control and 
morbidity risk reduction. It is especially challenging for adolescents with T1D to adhere to the 
meticulous routine necessary for optimal hemoglobin A1C (HbA1C) level management. FL3X 
is a program with strict eligibility criteria that employs adaptive behavioral intervention to 
improve HbA1c in adolescents with T1D. The utilization of motivation interviewing (MI), 
problem-solving skills training, and Behavioral Family System Therapy in the FL3X 
Intervention may improve T1D associated outcomes in participants. However, to successfully 
employ the methods of FL3X to optimize T1D management in other adolescent populations, 
the intervention must be integrated into T1D clinical practices. An existing T1D-care program 
is the Get Real About Diabetes (GRAD) program in the Greenville Health System (GHS). Like 
FL3X, GRAD employs MI in T1D counseling to help adolescents (recruited for having poor 
glycemic control according to their providers in GHS) better manage their T1D. GRAD was 
temporarily interrupted due to staffing changes, and the initial implementation and ongoing 
practice of GRAD are referred to as GRAD 1 & GRAD 2, respectively. Therefore, the goals 
of this FL3X-GRAD Integration study were to evaluate GRAD 1 and GRAD 2, compare the 
program design and delivery of FL3X and GRAD, and determine how the FL3X intervention 
may be feasibly implemented into the GRAD practice. To evaluate GRAD, demographic, 
attendance/participation, and clinical data were collected from GRAD 1 (N=77), GRAD 2 
(N=37), and non-GRAD (N=68), the control group from GHS. Differences in demographic, 
attendance/participation, and clinical data were non-significant between GRAD 1 and GRAD 
2. Furthermore, neither GRAD program showed significant benefit in improving in glycemic 
control compared to non-GRAD (P=0.2927). With respect to recruitment, the demographics 
of GRAD participants were similar to that of non-GRAD patients and the baseline glycemic 
control in GRAD was significantly poorer than in non-GRAD; however, subgroup analyses 
showed significantly poorer glycemic control in females, individuals less than 13 years of age, 
and non-Hispanic, white youth in GRAD, while differences in baseline HbA1c of other GRAD 
subgroups within the same sex, age, and race & ethnic categories were nonsignificant with 
respect to the same subgroups in non-GRAD. The evaluation and comparison of program 
design and delivery of GRAD 1 and 2 suggest that the staffing changes did not affect program 
delivery or participant outcomes significantly. Overall, the GRAD program shows no efficacy 
in improving glycemic control of participants. With respect to demographics, GRAD 
participants are generally reflective of the T1D youth in GHS; however, subgroup analyses 
suggest inadequate opportunity for referral/recruitment into GRAD of males, individuals older 
than 13 years of age, and minority youth from GHS. To inform the design and logistics of the 
clinical integration of FL3X, key informant interviews were conducted with available members 
of the GRAD staff (N=4). Responses indicated high-buy-in from staff and projected high-buy 
in from GRAD participants for integration of FL3X, concerns for financial, space, time, and 
personnel constraints that would be introduced by FL3X, preference for the current social 
worker and CDE to be FL3X coach, and preference for the FL3X coaching visit to be within 
the office visit. As such, a FL3X With Office Visit Model of clinical integration was selected 
as it follows the defined program design and delivery approaches of FL3X, while introducing 
the least constraints and including the FL3X coaching visit within the office visit. Thus, the 
FL3X With Office Visit Model is hypothesized to best integrate with the T1D care of youth in 
GHS and improve intervention recruitment and delivery with respect to GRAD. 
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INTRODUCTION 
Type 1 Diabetes Mellitus (T1D) is a chronic condition characterized by inadequate 
production of insulin, the hormone critical in the metabolism of glucose.1 Studies have shown 
significant increases in prevalence and incidence of T1D in youth in the U.S.4,5 Inadequate 
management of T1D can result in severe acute and chronic complications; thus, self-
management of T1D is critical for glycemic control and morbidity risk reduction. 6-8 However, 
it is especially challenging for youth with T1D to adhere to the meticulous routine necessary 
for optimal glycemic control due to the psychosocial and educational barriers characteristic 
of adolescence.9,10 As a result, glycemic control is frequently poor in adolescents with T1D.11  
FL3X is an adaptive behavioral intervention designed to improve glycemic control in 
adolescents with T1D.12 The intervention utilizes motivation interviewing (MI), problem-
solving skills training, and Behavioral Family System Therapy to improve glycemic control 
and other health outcomes in adolescents with T1D.13,14 However, to employ these methods to 
optimize T1D management in other adolescent populations, FL3X must be integrated into 
T1D care practices. An existing T1D-care program in the Greenville Health System (GHS) is 
the Get Real About Diabetes (GRAD) program, which also employs MI in T1D counseling 
to help adolescents, identified as having poor glycemic control according to their providers in 
GHS, better manage their T1D.15 As a result of already employing similar counseling 
strategies as FL3X, the GRAD practice is particularly receptive to the integration of FL3X. 
Thus, the goals of this FL3X-GRAD Integration study are to evaluate GRAD, compare FL3X 
and GRAD, and determine how the FL3X intervention may be feasibly implemented into the 
GRAD practice, by building upon the existing structure of this program in GHS.  
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METHODS 
 
FL3X: Randomized Clinical trial  
Overview 
FL3X is a randomized 18-month efficacy trial that employs adaptive behavioral intervention 
to improve HbA1c in adolescents with T1D. The utilization of motivational interviewing, 
Bright IDEAS problem-solving, BFST-D, a “toolbox” of additional resources, and diabetes 
education in the FL3X Intervention has shown promise in the management of glycemic 
levels as well as related health, behavioral, and psychosocial impacts in adolescents. 
Coordinated from the University of North Carolina at Chapel Hill (UNC), FL3X includes a 
total of 258 individuals randomized within each of 2 sites that participated in the FL3X Basic 
Pilot (University of Colorado Denver, Barbara Davis Center for Childhood Diabetes (UC-
BDC) and Cincinnati Children’s Hospital Medical Center, Division of Pediatric 
Endocrinology (CCHMC)).12 
 
Program Logistics 
Each intervention participant attends “FL3X-Basic”, which includes 4 sessions (40-60 min) 
over the first three months. These visits are also supplemented with short additional 
communication as necessary. Following FL3X-Basic, participants are iteratively assigned to 
either “FL3X Check-In” or “FL3X Regular” depending on their A1c measurements at 
defined intervals. Participants in FL3X-Check-in are doing well and attend short monthly 
sessions to receive minimal continued support to maintain successful glycemic management 
strategies. Participants in FL3X-Regular must attend at least 3-4 in-person full-length 
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sessions (40-60 min) every 6 months, with additional brief communication as necessary. 
FL3X participants randomized to the control group receive usual care.12 
 
Inclusion Criteria 
Participants are adolescents aged 13-16 years with a T1D diagnosis ≥ 1 year, poor glycemic 
control, and a parent/guardian willing to participate. Participants are excluded if pregnant or 
if they have type 2 diabetes, gestational diabetes, and/or other pre-existing chronic illnesses.12 
 
Get Real About Diabetes (GRAD) Program 
Overview of the Study 
The GRAD practice is a program in the Greenville Health System (GHS) that utilizes 
motivational interviewing, goal setting, and e-communication to improve glycemic 
management in adolescent patients with diabetes.15 
 
GRAD Practice Logistics 
Participants attend a minimum of four GRAD visits that are 4-8 weeks apart. During the 
initial visit, the patient and caregiver meet with the primary nurse provider (PNP) for a 
typical medical visit and an evaluation of diabetes knowledge followed by a meeting with the 
LCSW who explains the GRAD program and conducts motivational interviewing to guide 
goal setting. Following the initial visit, the patient meets with the PNP for a usual clinic visit 
as well as to review previous goals and diabetes education. The patient then meets with the 
LCSW for MI guided goal setting. Patients may also choose to supplement visits with 
reminders for visits and goals via e-communication. Additionally, family counseling is 
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offered and patients may choose to include caregivers in their visits. The GRAD clinic is held 
once a week, after which the primary care provider and the GRAD coach (a LCSW) convene 
and discuss the medical and behavioral parts of each patient’s visit. Changes in staffing 
temporarily interrupted GRAD; thus, the former period of GRAD is referred to as “GRAD 1” 
and the on-going period of GRAD is referred to as “GRAD 2” in this study.15 
 
Inclusion Criteria 
Patients identified as having poor diabetes management by their providers in GHS were 
invited into GRAD. Patients with type 2 diabetes were excluded.15 
 
 
FL3X-GRAD Integration Overview 
 
To evaluate GRAD and inform the design of the FL3X-GRAD integration, this study 
involved quantitative analysis of GRAD 1, GRAD 2, and non-GRAD (control) participant 
data and qualitative analysis of key informant interviews conducted with providers in the 
GRAD clinic. 
 
Quantitative Analysis of Program and Control Data 
Inclusion Criteria of GRAD Program Data and non-GRAD Control Data 
For the purposes of obtaining data for this study’s statistical analysis, the following inclusion 
criteria were set: data from GRAD 1 and GRAD 2 included that of all participants between 
11-19 years of age who attended at least 2 visits; the end-date of the on-going GRAD 2 was 
defined as July 1, 2017; and the control electronic health record data, or “non-GRAD” data, 
was collected from the Greenville Health System and limited to that of individuals with T1D 
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between 11-19 years of age whose health information was collected during the duration of 
GRAD 1 (July 1, 2008 – June 30, 2011) and/or GRAD 2 (June 1, 2013 – July 1, 2017). 
Applying these criteria, the data of 258 participants in FL3X (baseline data), 77 participants 
in GRAD 1, 37 participants in GRAD 2, and 68 non-GRAD adolescents (randomly selected 
from GHS patients who met non-GRAD inclusion criteria and were not enrolled in GRAD) 
were compiled. 
 
Analysis of Demographic Data 
The demographic data (D.O.B., date of T1D diagnosis, and race and ethnicity) of participants 
of FL3X, GRAD 1, GRAD 2, and non-GRAD were compiled, and univariate and/or 
frequency analysis of age, duration of T1D diagnosis, and race and ethnicity data from each 
group’s participants was performed. An overall ANOVA or χ2 test was then performed on 
the aforementioned calculated measures of the GRAD 1, GRAD 2, and non-GRAD groups. 
When a significant difference was detected (p < 0.05) in a ANOVA or χ2 measure, pair-wise 
T-Tests or χ2 were conducted within the same measure between GRAD 1 v. GRAD 2, 
GRAD 1 v. non-GRAD, and GRAD 2 v. non-GRAD groups. Significant differences (p < 
0.05) detected between the demographic measures were used to assess the demographic 
being recruited to and participating in each GRAD program. SAS v9.4 statistical software 
was utilized for the aforementioned statistical analyses.  
 
Analysis of Attendance and Participation Data  
The attendance and participation data (sessions attended, duration of participation) of 
participants of GRAD 1, GRAD 2, and non-GRAD were compiled, and univariate analysis of 
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sessions attended, proportion of participants per range of sessions attended, months of 
participation, and proportion of participants per range of months participated from each 
group’s participants was performed. An overall ANOVA or χ2 test was then performed on 
the aforementioned calculated measures of the GRAD 1, GRAD 2, and non-GRAD groups. 
When a significant difference was detected (p < 0.05) in a ANOVA or χ2 measure, pair-wise 
T-Tests or χ2 were conducted within the same measure between GRAD 1 v. GRAD 2, 
GRAD 1 v. non-GRAD, and GRAD 2 v. non-GRAD groups. Significant differences (p < 
0.05) detected between the demographic measures were used to assess the participation and 
attendance by participants of each GRAD program. SAS v9.4 statistical software was utilized 
for the aforementioned statistical analyses.  
 
Analysis of Start and End Clinical Measurement Data  
Start and end clinical measurement data (A1c, weight status, and BMIz) of individuals in 
GRAD 1, GRAD 2, and non-GRAD were compiled, and univariate analysis of pre, post, and 
change in age, duration of A1c, proportion of program participants per A1c range, weight 
status, and BMIz from each group’s participants was performed. An overall ANOVA or χ2 
test was then performed on the aforementioned calculated pre, post, and change measures of 
the GRAD 1, GRAD 2, and non-GRAD groups. When a significant difference was detected 
(p < 0.05) in an ANOVA or χ2 measure, pair-wise T-Tests or χ2 were conducted within the 
same measure between GRAD 1 v. GRAD 2, GRAD 1 v. non-GRAD, and GRAD 2 v. non-
GRAD groups. Significant differences (p < 0.05) detected between the pre, post, and change 
A1c measures were used to compare and evaluate the efficacy of the GRAD 1 and GRAD 2 
programs in improving A1c of participants.  
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Subgroup Analysis with respect to A1c 
Subgroup analysis of pre, post, and change in A1c by sex, ethnicity and race, duration of 
T1D diagnosis, age range, sessions attended, months of participation, participant A1c range, 
and weight status from each group’s participants was also performed. An overall ANOVA or 
χ2 test was then performed on the aforementioned calculated pre, post, and change measures 
of the GRAD 1, GRAD 2, and non-GRAD groups. When a significant difference was 
detected (p < 0.05) in an ANOVA or χ2 measure, pair-wise T-Tests or χ2 were conducted 
within the same measure between GRAD 1 v. GRAD 2, GRAD 1 v. non-GRAD, and GRAD 
2 v. non-GRAD groups. Significant differences (p < 0.05) detected between the subgroup 
measures were used to assess the effects of demographic characteristics, baseline clinical 
measurements, and participation and duration in each program on participant A1c. SAS v9.4 
statistical software was utilized for the aforementioned statistical analyses.  
 
Key Informant Interviews  
Administration of Key Informant Interviews 
Utilizing the FL3X Key Informant Interview Guide, key informant interviews were 
administered to four available providers currently in the GRAD practice. The interviews 
were designed to assess the receptiveness of the GRAD staff to integration with FL3X as 
well as discuss how FL3X may effectively and practically be incorporated into the GRAD 
practice.  
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Analysis of Key Informant Interviews 
The responses of each GRAD provider to every interview question were systematically 
presented in a table to highlight common themes and differences in provider experience and 
opinions regarding the integration of FL3X.  
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RESULTS 
 
Evaluation of GRAD 1 and GRAD 2 
77 individuals from GRAD 1, 37 individuals from GRAD 2, and 68 individuals from non-
GRAD met the eligibility criteria for this study. Demographic, attendance and participation, 
and clinical outcome data from these patients were collected and analyzed. 
 
Demographics of participants in GRAD 1, GRAD 2, and Non-GRAD (Table 1) 
The mean age at entry into program was significantly higher in both GRAD 1 (M=14.2, SD = 
1.9) and GRAD 2 (M=14.0, SD=1.9) than the mean age upon first visit of the non-GRAD 
group (M=12.9, SD=2.0). Participants with a T1D diagnosis ≥1 year comprised the vast 
majority of the GRAD 1, GRAD 2, and non-GRAD groups. However, the proportion of 
individuals with T1D diagnosis <1 year was significantly higher in GRAD 1 than Non-
GRAD. There were approximately 48.5% males and 51.5% females in GRAD 1, GRAD 2, 
and non-GRAD. Additionally, White, Non-Hispanic individuals comprised the majority of 
the GRAD 1, GRAD 2, and non-GRAD populations, followed by Black, Non-Hispanic 
youth. Hispanic youth and Other, Non-Hispanic youth comprised less than 10% of the 
populations in GRAD 1, GRAD 2, and non-GRAD. The proportions of individuals in each 
ethnic and race category did not differ significantly across GRAD 1, GRAD 2, and non-
GRAD (χ² = 0.6946). 
 
Attendance and Participation in GRAD 1 and GRAD 2 (Table 2) 
The average number of sessions attended or average duration of participation did not differ 
significantly between GRAD 1 and GRAD 2. 
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Clinical characteristics of participants in GRAD 1, GRAD 2, and Non-GRAD (Table 3) 
The mean baseline HbA1c was significantly higher in both GRAD 1 (M=9.9, SD = 1.6) and 
GRAD 2 (M=9.9, SD=1.6) than the mean HbA1c upon first visit of the non-GRAD group 
(M=9.0, SD=1.6). However, GRAD 1 and GRAD 2 showed no significant improvement in 
mean HbA1c between first and last visits with respect to each other and non-GRAD (P = 
0.2927). Additionally, there were significantly more participants with HbA1c ≥ 9% at 
baseline in GRAD 1 (70.1%) and GRAD 2 (78.4%) than in non-GRAD (36.8%).  
 
Assessment of Differences in Pre- and Post- HbA1c within GRAD 1, GRAD 2, Non-GRAD 
(Table 4) 
There was no significant improvement in HbA1c within GRAD 1, GRAD 2, or Non-GRAD. 
 
HbA1c Averages with respect to demographics of GRAD 1, GRAD 2, and Non-GRAD  
(Table 5) 
At baseline, the mean HbA1c of females in GRAD 1 (M=9.7140, SD=1.2896) and GRAD 2 
(M=9.6, SD=2.0) was significantly higher than the mean HbA1c of females in non-GRAD 
(M=8.6, SD=1.3). However, differences in mean baseline HbA1c of males across GRAD 1, 
GRAD 2, and non-GRAD were nonsignificant (P=.1349). In addition, the mean baseline 
HbA1c of white, non-Hispanic individuals in GRAD 1 (M=9.9, SD=1.7) and GRAD 2 
(M=9.6, SD=1.3) was significantly higher than the mean baseline HbA1c of white, non-
Hispanic individuals in non-GRAD (M=8.7, SD=1.4). However, differences in mean baseline 
HbA1c values of individuals across other race and ethnicity categories in GRAD 1, GRAD 2, 
and non-GRAD were nonsignificant. The mean baseline HbA1c of individuals <13 years old 
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in GRAD 1 (M=9.7, SD=1.3) was also significantly worse than the mean baseline HbA1c of 
individuals <13 years old in non-GRAD (M=8.8, SD=1.3). However, differences in mean 
baseline HbA1c of individuals older than 13 years in GRAD 1, GRAD 2, and non-GRAD 
were nonsignificant. 
 
HbA1c Averages with respect to Clinical Characteristics of GRAD 1, GRAD 2, and Non-
GRAD groups (Table 7) 
The mean baseline HbA1c of individuals with normal baseline weight status in GRAD 1 
(M=10.0, SD=1.5) and GRAD 2 (M=10.0, SD=1.4) were significantly higher than the mean 
baseline HbA1c of individuals with normal baseline weight status in non-GRAD (M=9.2, 
SD=1.7). Additionally, mean baseline HbA1c of individuals with overweight baseline weight 
status in GRAD 1 (M=10.0, SD=.8) was significantly higher than the mean baseline HbA1c 
of individuals with overweight baseline weight status in non-GRAD (M=8.3, SD=1.0). In 
addition, an earlier evaluation of GRAD (during GRAD 1), conducted by the GRAD staff, 
found peak HbA1c improvements in patients with baseline HbA1c in the fourth quartile. 
However, subgroup analysis by high HbA1c range in this study showed no significant 
improvement in glycemic control among participants with baseline HbA1c ≥10% in both 
GRAD 1 & 2 when compared to those in Non-GRAD. 
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Key Informant Interviews 
Four providers currently in the GRAD clinic participated in the key informant 
interviews. The respondents consisted of the Pediatric Endocrinologist and head of the 
GRAD clinic; the Licensed Independent Social Worker – Clinical Practice/Advance Practice 
and Certified Diabetes Educator (LISW-CP/AP & CDE); the Registered Dietician and 
Certified Diabetes Educator (RDCDE); and the Registered Nurse Care Manager (RN Care 
Manager). Responses regarding receptiveness and logistics with the clinical integration of 
FL3X into the GRAD program were similar (Tables 8-10).  
 
Interest of GRAD Staff for FL3X-GRAD Integration (Table 8). 
Participants reported strong interest scores (9 or 10 out of scale of 1-10), citing the 
positive feedback that GRAD has received with their current behavioral management 
approach that employs a similar, but less structured and consistent MI approach as FL3X. 
Therefore, the GRAD team is excited to incorporate the FL3X intervention into their 
program. 
 
Integration Logistics, FL3X Coach Selection, and Coach Training (Table 9) 
The most commonly mentioned barriers were cost for training, space utilization, 
personnel needs, and costs for toolboxes. The Pediatric Endocrinologist reported that if FL3X 
were to replace the GRAD program, funding for GRAD would go towards implementing 
FL3X. Each of the interviewed staff stated that the LISW-CP/AP & CDE would serve as the 
FL3X coach because of her psych-social background and experience with diabetes education; 
however, serving as the FL3X coach would be in addition to her current role in the clinic. 
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The team, including the LISW-CP/AP & CDE, estimate that availability for FL3X coach 
training to be one hour per week. The LISW-CP/AP & CDE also mentioned interest in an 
initial workshop with intensive training over several days followed by further training and 
feedback over time, when available from clinic duties. Additionally, all participants indicated 
a preference for the provider visit and the coach visit to be back-to-back as it is difficult to 
schedule two separate visits for children in school. The LISW-CP/AP & CDE also suggested 
that some clinic visits could solely consist of the coaching session.  
 
Projected Patient Buy-In for FL3X Intervention and Other Miscellaneous Considerations 
(Table 10) 
The GRAD staff predicts high buy-in for FL3X from patients currently in the GRAD 
program and moderate buy-in from general patients not currently in the GRAD program. The 
Pediatric Endocrinologist estimates that of the general patients who would be eligible for 
FL3X, 50% would buy into the program. He also states that this projection of patient 
recruitment into FL3X could be improved with provider suggestion. Additionally, The 
GRAD staff believes that monthly FL3X visits for patients are feasible as this is the current 
frequency of visits in the GRAD program (Table 3). Each staff member reported that the 
family component of the FL3X protocol, allowing the patient to decide what is shared with 
the parent and allowing the patient and the parent to decide what will be shared with their 
usual care team, would work well in their clinic as GRAD currently employs this approach 
with patients.  
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DISCUSSION 
 
Evaluation of the GRAD 1 and GRAD 2 Programs 
Efficacy of the GRAD Programs in Improving Glycemic Control 
This study found that neither GRAD 1 nor GRAD 2 showed significant benefit in 
improving glycemic control of participating adolescents with respect to each other or to the 
non-GRAD control group. Furthermore, there was no significant improvement in glycemic 
control between baseline and final measures of adolescents in GRAD 1, GRAD 2, or non-
GRAD. More specific analysis of change in HbA1c with respect to demographic 
characteristics, baseline clinical measurements, or participation/attendance also did not show 
significant benefit to glycemic control of any subgroup in GRAD. These results suggest that 
program efficacy did not change between GRAD 1 and GRAD 2, that the efficacy of the 
GRAD program is not better than that of usual T1D care of adolescents in the Greenville 
Health System, and that no specific subgroup in GRAD achieved greater improvement in 
glycemic control than those in non-GRAD. It is important to note that an earlier evaluation of 
GRAD (conducted by GRAD staff during GRAD 1) found peak HbA1c improvements in 
participants who attended at least 10 visits; however, the evaluation of GRAD in this study 
showed that only 29.9% of those in GRAD 1 and 43.2% of those in GRAD 2 attended at least 
10 visits. Thus, the lack of significant improvement in HbA1c in the GRAD programs may 
be attributed to the potential inadequate participation by the majority of the participants.  
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Referral and Recruitment into the GRAD Program 
Participants in GRAD 1 and GRAD 2 exhibited significantly higher HbA1c at 
baseline than adolescents in non-GRAD, demonstrating the overall successful recruitment of 
eligible patients exhibiting poor glycemic control (HbA1c > 7.5% as defined by the ADA) 
from GHS into GRAD.30 Additionally, the age distribution, duration of T1D diagnosis, and 
demographics of adolescents in GRAD 1, GRAD 2, and non-GRAD were similar, signifying 
that the participants in GRAD were generally reflective of the T1D youth population in GHS.  
However, some subgroup analyses of baseline HbA1c indicate unequal opportunity 
for certain T1D youth exhibiting poor glycemic control in GHS to be recruited into the 
GRAD program. With respect to sex, baseline HbA1c was significantly higher in females in 
GRAD 1 and GRAD 2 than females in non-GRAD, as expected; conversely, differences in 
baseline HbA1c of males across both GRAD programs and non-GRAD were nonsignificant. 
Together, these subgroup comparisons suggest that female youth exhibiting poor glycemic 
control may have been more likely to be referred/recruited into GRAD than male youth 
exhibiting poor glycemic control. Similar inconsistent subgroup comparisons of baseline 
HbA1c were found in ethnicity & race and in age range categories. These results suggest that 
white, non-Hispanic youth exhibiting poor glycemic control may have been more likely to be 
referred/recruited into GRAD than minority youth exhibiting poor glycemic control and that 
youth less than 13 years of age exhibiting poor glycemic control may have been more likely 
to be referred/recruited into GRAD 1 than older youth exhibiting poor glycemic control. 
Therefore, while the GRAD program has generally been successful in recruiting patients 
exhibiting poor glycemic control from GHS, male youth, minority youth, and older youth in 
GHS may be referred less to GRAD and/or experience greater barriers to participation in 
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GRAD than other subgroups. Potential barriers to participation may include: lack of 
receptiveness to intervention treatment and/or time constraints due to school, social activities, 
and other responsibilities (family, job, extracurricular) characteristic of adolescence.  
 
Comparison of GRAD 1, GRAD 2, and FL3X Program Methods and Delivery 
Key differences in eligibility criteria, interventionists, visit content, visit frequency, outcome 
measures, and fidelity between GRAD 1, GRAD 2, and FL3X are noted in the Appendix 1. 
GRAD 1 v. GRAD 2 
Overall, the methods and program delivery of GRAD 1 and GRAD 2 are very similar. 
The switch of the interventionist from the LCSW who only lead MI guided goal setting to the 
LCSW/CDE who leads both MI guided goal setting and diabetes education is the key 
difference between GRAD 1 and GRAD 2.  
 
GRAD v. FL3X 
With respect to FL3X, the recruitment of patients into GRAD may have less 
consistency as eligibility is based on poor glycemic control, defined at the discretion of the 
primary diabetes care provider. In contrast, FL3X has specific age, baseline HbA1c, duration 
of T1D diagnosis, and exclusion criteria for recruitment of T1D patients into the program.  
Program interventionists and their roles also differ between GRAD and FL3X. GRAD 
interventionists include both the PNP who conducts the office visit and the LCSW/CDE who 
is the coach whereas there is only one FL3X interventionist, the FL3X coach. In GRAD, the 
office visits and diabetes coaching visits are back-to-back in the same clinic, and there is 
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communication between the PNP and LCSW/CDE regarding the progress of the participant; 
however, in FL3X, the coaching visit is separate from the office visit.  
Additionally, while both the FL3X and GRAD coaching visits employ MI guided 
goal setting and diabetes education, the content of FL3X visits is significantly more 
structured and employs BRIGHT Ideas problem-solving skills training, behavioral family 
systems therapy, diabetes toolboxes, and phone use to create reminders for diabetes 
management unlike GRAD. With respect to program schedule, the frequency of GRAD visits 
is similar to, but less consistent than the monthly FL3X visits. FL3X also employs an 
adaptive design, which tailors treatment to the progress of the participant in achieving set 
goals, that GRAD does not have in its design.  
Finally, FL3X employs extensive analysis of participant outcomes and coach fidelity 
unlike GRAD.  
 
Evaluation of Proposed FL3X-GRAD Integration Designs 
Three potential designs of the integration of FL3X into GRAD are considered for this 
study. The first design is FL3X in parallel with usual diabetes care (as FL3X currently 
operates) of eligible patients in GHS. The second design is FL3X as usual diabetes care, in 
which all T1D patients in the GHS pediatric endocrinology clinic receive FL3X care. The 
third design is the FL3X With Office Visit Model, in which the FL3X coach meets with 
eligible patients during their office visits with the provider (as GRAD currently operates).  
Taking account of the differences in program design and delivery of FL3X and 
GRAD as well as the literature on clinical integration, appendices 2-5 provide important 
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considerations that would be introduced by FL3X (with respect to the current operation of 
GRAD) with each integration approach. 
Upon comparison of the demands placed by each integration approach, FL3X as 
usual diabetes care seems to be the least practical design as it requires the most resources for 
every patient to receive FL3X care. Furthermore, some patients with adequate glycemic 
control may not have a need for FL3X care, which may limit resources for patients with poor 
glycemic control and greater need of FL3X care. The “FL3X in parallel with usual diabetes 
care” model and the FL3X With Office Visit Model seem to impose the least barriers to 
clinical integration. However, given the unanimous preference of the GRAD staff for the 
provider visit and the coach visit to be back-to-back (for convenience and benefit of the 
patients in school), the FL3X With Office Visit Model would likely best integrate with the 
current practices of the GRAD program.  
 
Logistics of Implementation of the FL3X With Office Visit Model 
Eligibility 
Eligibility criteria would follow that of the FL3X intervention, allowing for greater 
consistency in patient referral (from usual diabetes care in GHS) into the FL3X program. It is 
important to note that some current GRAD participants may be excluded with FL3X criteria 
if exceptions are not made to allow these participants to switch into FL3X. Conversely, there 
is also a possibility of more participants being recruited than the clinic currently has the 
capacity to treat optimally and frequently.  
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Interventionists and Intervention Content 
According to results from the key informant interviews, the current LISW-CP/AP & 
CDE in GRAD would be the FL3X coach and allotted approximately four hours a month 
and/or an initial intensive workshop for training. The coach would be trained to administer 
the same visit content as in the FL3X intervention. Additionally, parents would continue to 
be present and involved in some coaching sessions with children as both FL3X and GRAD 
currently operate. Additional funding may be required for coaching training and FL3X 
content resources. 
 
Visit Frequency 
The GRAD clinic will adopt the monthly visit frequency as well as the adaptive 
component of the FL3X intervention for consistent and tailored care of each participant. 
Thus, all participants will attend “FL3X-Basic”, consisting of four sessions over the initial 
three months. Depending on HbA1c following the initial three months of “FL3X Basic”, 
participants will be assigned to either “FL3X Check-In” or “FL3X Regular”. Participants in 
“FL3X Check-In” are doing well and will attend short monthly sessions to receive minimal 
continued support to maintain successful glycemic management strategies. Participants in 
“FL3X-Regular” must attend at least 3-4 in-person full-length sessions (40-60 min) every 6 
months, with additional brief communication as necessary. Depending on future A1c 
measurements at defined intervals, participants may either stay in “FL3X Check-In” or 
“FL3X Regular” or be reassigned. Although responses from the key informant interviews 
confirm that monthly visit frequency will be obtainable as it is the approximate frequency of 
GRAD visits, there may be new scheduling, financial, and space constraints given the greater 
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length of a FL3X visit (with respect to the current length of a GRAD coaching visit) and the 
potential for an increase in participants. Therefore, there may be a need for more space and 
more staff to increase the clinic capacity.  
 
Outcome Measures and Fidelity 
The clinic should adopt the practice of recording the outcomes measures as well as 
the fidelity of visits as is practiced in FL3X. However, collecting and analyzing this data to 
monitor program delivery and outcomes may impose additional financial and time demands 
on the staff of the clinic. 
 
Staff and Patient Buy-In to FL3X With Office Visit Model  
The high buy-in of the current GRAD staff and the projected high buy-in of current 
GRAD participants for FL3X, as reported by the key informant interviews, should help ease 
the FL3X-GRAD integration. Furthermore, buy-in of non-GRAD patients who would be 
eligible for FL3X can be improved with provider recommendation in GHS, as suggested by a 
GRAD staff member.  
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STRENGTHS AND LIMITATIONS 
With respect to the evaluation of GRAD, a major limitation of this evaluation was 
that the patients with poor glycemic control recruited into GRAD are no longer included in 
the non-GRAD, control data. This limitation may have caused the average change in HbA1c 
in non-GRAD to seem as beneficial as that of GRAD, when, in reality, the GRAD 
participants could have experienced significantly less benefit or a decline in glycemic control 
without the intervention in GHS. Another limitation of this study is that only HbA1c was 
consistently measured in GRAD and utilized to assess the efficacy of GRAD in this study. 
However, there may have been improvements in psych-social outcomes of participants that 
were not evaluated in this study of GRAD. Specific outcome measures measured in FL3X 
that would have been critical in evaluating psych-social changes in GRAD participants 
include: Pediatric Diabetes Quality of Life (PDQ), Pediatric Quality of Life (Peds QLTM 
Generic), Diabetes Self-Management Survey (DSMP-SR), Diabetes Family Conflict, 
Diabetes Family Responsibility, and Depression (CES-D) questionnaires as improvements in 
these outcomes are also correlated with increased adherence to therapy in individuals with 
T1D.9,21-24,44 Furthermore, insulin regimen type (MDI vs. CSII) and change in insulin regimen 
data were not collected in this study. These data are critical as previous studies have found 
regimen change from MDI to CSII to be correlated with improvements in glycemic control; 
thus, changes in insulin regimen from MDI to CSII by some patients in GRAD and non-
GRAD may have had confounding effects in improving or stabilizing glycemic control that 
cannot be attributed to the GRAD intervention or non-GRAD care in GHS. Additionally, 
short-term outcome measures such as incidence of hypoglycemia, DKA, or hospital 
admission were also not collected in this study. The GRAD program may have been 
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successful in significantly reducing the frequency of short-term, severe complications, which 
would be critical for morbidity risk reduction in youth with T1D.  
With respect to designing the FL3X-GRAD Integration, the strength of this study was 
that key informant interviews were conducted with GRAD staff members with different roles 
in the clinic, allowing for multiple perspectives to be considered in choosing and designing 
the FL3X With Office Visit Model. Conversely, the limitation to these data is that the key 
informant interviews were conducted with only four GRAD staff members, the responses of 
whom may not adequately represent those of the entire GRAD staff.  
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CONCLUSION 
The evaluation of GRAD in this study suggests that GRAD does not appear to 
provide significant benefit in improving glycemic control of youth with T1D; however, it is 
important to note that the major limitations in the non-GRAD control data and the lack of 
psych-social, insulin regimen, and short-term complication/outcome data may incompletely 
describe the efficacy of GRAD. Results from FL3X are pending, so it cannot be concluded 
that FL3X would provide significantly more benefit than GRAD with respect to glycemic 
control or other health outcomes. However, since this study also suggested unequal 
opportunity for referral and/or recruitment of certain demographics of patients into GRAD, it 
can be hypothesized that the defined eligibility criteria of FL3X would improve consistency 
in referral of T1D youth exhibiting poor glycemic control from GHS. Furthermore, the 
implementation of FL3X should improve consistency and record of program delivery and 
secondary participant outcomes, allowing for a more complete evaluation of program 
efficacy than that of this study.  
 The proposed FL3X With Office Visit Model of clinical integration should introduce 
the least time, space, and financial constraints to the pediatric endocrinology clinic in GHS. 
Furthermore, the hybrid model is optimal as having the FL3X coaching visit back-to-back 
with the office visit is preferred by the staff and will likely be the most convenient for 
patients who are in school. Finally, the high buy-in of the GRAD staff and the projected high 
buy-in of current GRAD participants should ease the implementation of FL3X into the 
GRAD infrastructure. The successful clinical integration of the proposed FL3X With Office 
Visit Model has the potential to improve glycemic control and related health and psych-
social outcomes in youth with T1D in GHS.  
  42 
FUTURE STEPS 
 Utilizing the evaluation of GRAD and the proposed FL3X With Office Visit Model in 
this study, a grant for the FL3X-GRAD integration should be obtained if financial, space, 
and time constraints introduced by the proposed model exceed the current capacity and 
resources of the GRAD clinic. However, prior to implementation, it will be critical to identify 
barriers to participation in male, minority, and older youth in GHS to correct the unequal 
opportunity for recruitment and program attendance suggested in the evaluation of GRAD. 
Upon implementation of the FL3X With Office Visit Model, the clinical integration will be 
monitored to assess program delivery and patient recruitment. In addition, demographic, 
participation, clinical outcome, and fidelity data will be recorded consistently for evaluation 
of the FL3X With Office Visit Model in comparison to the former GRAD program. 
Furthermore, results from the FL3X intervention have recently become available. 
Thus, future work also includes analyzing these results to evaluate FL3X and to learn how 
the program design and delivery may be improved for FL3X 2.0. One such future direction 
of FL3X is the incorporation of CGM data in insulin dosing, an approach that was approved 
by the FDA after the initiation of FL3X. The new approaches of FL3X 2.0 may also be 
incorporated into the FL3X-GRAD Integration in the future. 
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DATA TABLES 
 
Table 1: Demographics of participants in GRAD 1, GRAD 2, and Non-GRAD.  
	 	 	 GRAD	1	
N=77	
GRAD	2	
N=37	
Non-
GRAD	
N=68	
Overall	
Comparison	
(GRAD	1,	GRAD	2,	
Non-Grad)	
P-value	
α	=	0.05	
Age	Distribution		 Age	at	Entry	(Years)	
Mean	(SD)	
14.2	
(1.9)	
	
14.0	
(1.9)	
	
12.9	
(2.0)	
	
<.0001	^#	
	
Proportion	aged	13-16	
years	
(%)	
48.1%	
	
48.7%	
	
48.5%	
	
0.9975	
	
Duration	of	T1D	
Diagnosis	(%)	
		
	
Duration	<1	
year		
	
Proportion	 9.1%	
	
2.7%	
	
0%	
	
0.0245	^	
(χ2	comparing	
proportions)	
Mean	Years	
(SD)	
0.6	
(0.2212)	
1.0	
(N=1;		
SD:	NA)	
-	
Duration	≥1	
year	
Proportion	 90.9%	
	
97.3%	
	
100%	
	
Mean	
(SD)	
5.7	
(3.2)	
5.4	
(3.6)	
-	
Demographics	
(%)	
	
	
	
	
	
	
	
	
	
	
Sex	 Male	 44.2%	
	
51.4%	
	
50.0%	
	
0.6946	
	
Female	 55.8%	
	
48.7%	
	
50.0%	
	
Ethnic	&	
Race	
Categories	
Hispanic	 6.5%	
	
8.1%	
	
1.5%	
	
0.1821	^	
	
White,	
Non-
Hispanic	
63.6%	 70.3%	
	
82.4%	
	
Black,	Non-
Hispanic,		
26.0%	
	
18.9%	
	
16.2%	
	
Other,	Non-
Hispanic	
3.9%	
	
2.7%	
	
0.0%	
	
Ethnicity	
Not	
reported	
0.0%	
	
0.0%	
	
0.0%	
	
Statistically significant pairwise comparisons (P ≤ 0.05) denoted by: * (GRAD1 v. GRAD 2); 
^ (GRAD 1 v. Non-GRAD); # (GRAD 2 v. Non-GRAD).  
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Table 2: Attendance and Participation in GRAD 1 and GRAD 2.  
	 	 GRAD	1	 GRAD	2	 GRAD	1	v.	
GRAD	2	
P-value	
α	=	0.05	
Attendance	in	Program	 Mean	Sessions	
Attended	(SD)	
7.6	(5.1)	 8.2	(4.6)	 0.5591	
Range	(min.	#	to		max.	
#	of	sessions	that	
were	attended)	
2	-	21	 2	-	18	 -	
Number	of	Sessions	Attended	
(%)	
2	-	3	sessions	 22.1%	 21.6%	 0.3084	
4	–	6	sessions	 31.2%	 29.7%	
7	–	9	sessions	 16.9%	 5.4%	
10	sessions	 2.6%	 8.1%	
11-13	sessions	 11.7%	 21.6%	
14+	sessions	 15.6%	 13.5%	
Participation	in	Program	(Months)	
Mean	(SD)	
11.8		
(8.7)	
15.2		
(10.1)	
0.0622	
Ranges	of	Participation	
(%)	
0	–	2.9	Months	 11.7%	 5.4%	 0.4112	
3	–	5.9	Months	 20.8% 13.5% 
6	–	11.9	Months	 27.3% 29.7% 
12-18	Months	 19.5% 16.2% 
>	18	Months	 20.8% 35.1% 
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Table 3: Clinical characteristics of participants in GRAD 1, GRAD 2, and Non-GRAD. 
	 GRAD	1	
N=77	
	
GRAD	2	
N=37	
	
Non-GRAD	
N=68	
	
Overall	Comparison	
(GRAD	1,	GRAD	2,	Non-
Grad)	
P-value	
α	=	0.05	
	
Pre	 Post	 Change	 Pre	 Post	 Change	 Pre	 Post	 Change	 Pre	 Post	 Change	
HbA1c	(%)	
Mean	(SD)	
9.9 
(1.6)	
9.8		
(1.9)	
-0.1		
(1.7)	
9.9		
(1.6)	
10.1	
(1.8)	
0.2		
(1.6)	
9.0		
(1.6)	
9.2		
(1.8)	
0.2		
(1.2)	
0.0016	
^#	
0.0378	 0.2927	
Distribution	
of	
Participant	
HbA1c	
%	
	
Proportion	
with	<9%		
	
29.9%	 37.7%	 7.8%	 21.6%	 35.1%	 13.5%	 63.2%	 52.9%	 NA	 <.0001	
^#	
0.1016	 NA	
Proportion	
(%)	with	
≥9%	
	
70.1%	 62.3%	 -7.8%	 78.4%	 64.9%	 -13.5%	 36.8%	 47.1%	 NA	
BMIz	
Mean	(SD)	
0.70	
(1.14)	
0.98	
(1.02)	
0.28	
(0.50)	
0.66	
(0.88)	
0.93	
(0.96)	
0.27	
(0.51)	
0.56	
(1.01)	
0.76	
(0.90)	
0.20	
(0.45)	
0.7079	 0.3541	 0.5480	
Statistically significant (P ≤ 0.05) pairwise comparisons of baseline or change data denoted 
by: * (GRAD1 v. GRAD 2); ^ (GRAD 1 v. Non-GRAD); # (GRAD 2 v. Non-GRAD).  
 
 
 
Table 4: Assessment of Differences in Pre- and Post- HbA1c within GRAD 1, GRAD 2, 
Non-GRAD.  
	 GRAD	1	
N=77	
	
GRAD	2	
N=37	
	
Non-GRAD	
N=68	
	
Pre-	v.	Post-	HbA1c	
T-Test	
α	=	0.05	
	
0.3752	 0.3994	 0.2838	
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Table 5: HbA1c Averages with respect to demographics of GRAD 1, GRAD 2, and Non-
GRAD. 
	 GRAD	1	
N=77	
	
GRAD	2	
N=37	
	
Non-GRAD	
N=68	
	
Overall	Comparison	
(GRAD	1,	GRAD	2,	Non-
Grad)	
P-value	
α	=	0.05	
	
Pre	 Post	 Change	 Pre	 Post	 Change	 Pre	 Post	 Change	 Pre	 Post	 Change	
HbA1c	by	
Sex	
Mean	
(SD)	
Male	 10.2	
(2.0)	
10.0	
(2.1)	
-0.2	
(2.2)	
10.1	
(1.1)	
10.7	
(1.7)	
0.6	
(1.3)	
9.4	
(1.7)	
9.4	
(1.9)	
0.0	
(1.1)	
0.1349	 0.0505	 0.1893	
Female	 9.7	
(1.3)	
9.6	
(1.7)	
-0.1	
(1.3)	
9.6	
(2.0)	
9.4	
(1.8)	
-0.2	
(1.8)	
8.6	
(1.3)	
9.0	
(1.8)	
0.4	
(1.3)	
0.0040	
^#	
0.3639	 0.2081	
HbA1c	by	
Ethnicity	
and	Race	
Mean	
(SD)	
Hispanic	 9.2	
(1.7)	
9.9	
(2.5)	
0.7	
(1.1)	
11.6	
(2.9)	
11.9	
(3.5)	
0.2	
(2.2)	
9.9	
(N=1;	
SD:	NA)	
10.2	
(N=1;	
SD:	NA)	
0.3	
(N=1;	
SD:	NA)	
0.3586		 0.6518	 0.9120	
White, 
Non-
Hispanic	
9.9	
(1.7)	
9.7	
(1.6)	
-0.2	
(1.7)	
9.6	
(1.3)	
9.6	
(1.6)	
0.0	
(1.3)	
8.7	
(1.4)	
	
8.8	
(1.7)	
0.1	
(1.2)	
0.0003	
^#	
0.0247	
^	
0.4557	
Black, 
Non-
Hispanic, 	
10.0	
(1.6)	
9.5	
(2.3)	
-0.5	
(1.9)	
10.2	
(1.8)	
11.2	
(1.2)	
1.0	
(2.4)	
10.4	
(1.6)	
10.6	
(2.1)	
0.2545	
(1.4)	
0.8	 0.1414	 0.1973	
Other, 
Non-
Hispanic	
10.7	
(1.7)	
11.6	
(2.1)	
0.9	
(1.3)	
9.1	
(N=1;	
SD:	NA)	
10.0	
(N=1;	
SD:	NA)	
0.9	
(N=1;	
SD:	NA)	
-	 -	 -	 0.5132	 0.5833	 0.9845	
HbA1c	by	
Duration	
of	T1D	
Diagnosis	
Mean	
(SD)	
Duration 
<1 year  
 
9.3	
(1.6)	
8.9	
(3.0)	
-0.3	
(2.1)	
6.2	
(N=1;	
SD:	NA)	
8.2	
(N=1;	
SD:	NA)	
2.0	
(N=1;	
SD:	NA)	
-	 -	 -	 0.1304	 0.8241	 0.3367	
Duration 
≥1 year 
10.0	
(1.6)	
9.8	
(1.8)	
-0.2	
(1.7)	
10.0	
(1.5)	
10.2	
(1.8)	
0.2	
(1.6)	
9.0	
(1.6)	
9.2	
(1.8)	
0.2	
(1.2)	
0.0005	
^#	
0.0187	
^>	
0.3821	
HbA1c	by	
Age	
Range	
Mean	
(SD)	
<13 
years 
9.7	
(1.3)	
9.4	
(1.8)	
-0.3	
(1.5)	
9.4	
(1.3)	
9.7	
(1.2)	
0.3	
(1.8)	
8.8	
(1.3)	
9.1	
(1.8)	
0.3	
(1.2)	
0.0321	
^	
0.5671	 0.2298	
13-16 
years 
10.0	
(1.8)	
9.9	
(1.9)	
-0.1	
(2.1)	
10.0	
(1.8)	
10.4	
(2.2)	
0.4	
(1.6)	
9.3	
(1.8)	
9.3	
(1.9)	
0.0	
(1.2)	
0.1900	 0.1445	 0.5241	
>16 
Years 
10.1	
(1.7)	
10.0	
(2.0)	
-0.1	
(1.2)	
10.6	
(1.2)	
10.2	
(1.8)	
-0.4	
(1.2)	
-	 -	 -	 0.4985	 0.8775	 0.4890	
Statistically significant (P ≤ 0.05) pairwise comparisons of baseline or change data denoted 
by: * (GRAD1 v. GRAD 2); ^ (GRAD 1 v. Non-GRAD); # (GRAD 2 v. Non-GRAD).  
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Table 6: HbA1c Averages with respect to attendance and participation in GRAD 1 and 
GRAD 2.  
	 GRAD	1	
N=77	
	
GRAD	2	
N=37	
	
GRAD	1	v.	GRAD	2	
P-value	
α	=	0.05	
	
Pre	 Post	 Change	 Pre	 Post	 Change	 Pre	 Post	 Change	
HbA1c	by	
Sessions	
Attended	
Mean	(SD)	
	
2	-	3	
sessions	
10.1	
(1.9)	
10.1	
(2.1)	
0.0	
(1.2)	
9.8	
(1.0)	
9.5	
(2.0)	
-0.3	
(1.8)	
0.7032	 0.5310	 0.6550	
4	–	6	
sessions	
9.8	
(1.4)	
9.2	
(1.8)	
-0.6	
(1.5)	
10.0	
(2.1)	
10.8	
(2.0)	
0.9	
(1.7)	
0.7223	 0.0257	 0.0200	
7	–	9	
sessions	
9.7	
(1.3)	
9.9	
(2.1)	
0.2	
(1.3)	
11.6	
(0.5)	
11.9	
(1.6)	
0.4	
(2.1)	
0.0822	 0.2238	 0.8635	
10	sessions		 10.0	
(2.5)	
9.7	
(1.1)	
-0.3	
(1.3)	
10.2	
(1.0)	
10.0	
(1.0)	
-0.2	
(1.0)	
0.8797	 0.7796	 0.9651	
11-13	
sessions	
9.7	
(1.9)	
9.7	
(0.6)	
0.0	
(2.1)	
9.3	
(1.6)	
9.6	
(1.7)	
0.3	
(1.6)	
0.6076	 0.8696	 0.7133	
14+	sessions	 10.5	
(1.8)	
10.3	
(2.3)	
-0.2	
(2.9)	
9.9	
(1.7)	
9.7	
(1.3)	
-0.3	
(1.1)	
0.5826	 0.5813	 0.9392	
HbA1c	by	Months	
of	Participation	
Mean	(SD)	
	
0	–	2.9	
Months 
9.8	
(1.7)	
9.8	
(1.8)	
0.0	
(1.5)	
10.2	
(1.0)	
9.3	
(2.7)	
-0.9	
(1.7)	
0.7870	 0.7658	 0.5026	
3	–	5.9	
Months 
9.3	
(1.1)	
8.7	
(1.9)	
-0.6	
(1.2)	
10.8	
(2.6)	
10.1	
(2.8)	
-0.7	
(0.8)	
0.2615	 0.2125	 0.8450	
6	–	11.9	
Months 
10.3	
(1.8)	
10.0	
(9.3)	
-0.3	
(1.4)	
9.8	
(1.4)	
10.7	
(9.5)	
0.9	
(2.0)	
0.4201	 0.2894	 0.0639	
12-18	
Months 
10.2	
(2.2)	
9.6	
(1.7)	
-0.6	
(2.4)	
10.0	
(1.2)	
10.8	
(1.9)	
0.8	
(0.9)	
0.1764	 0.1966	 0.0735	
>	18	
Months 
9.9	
(1.1)	
10.6	
(2.1)	
0.7	
(1.8)	
9.5	
(1.6)	
9.4	
(1.2)	
-0.1	
(1.4)	
0.4801	 0.0741	 0.2007	
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Table 7: HbA1c Averages with respect to Clinical Characteristics of GRAD 1, GRAD 2, and 
Non-GRAD groups. 
	 GRAD	1	
N=77	
	
GRAD	2	
N=37	
	
Non-GRAD	
N=68	
	
Overall	ANOVA	
(GRAD	1,	GRAD	2,	Non-Grad)	
P-value	
α	=	0.05	
	
Pre	 Post	 Change	 Pre	 Post	 Change	 Pre	 Post	 Change	 Pre	 Post	 Change	
HbA1c	by	
Participant	
HbA1c	
Range	at	
Baseline	
Mean	(SD)	
Proportion	with	
<9%	
8.3	
(0.6)	
8.5	
(1.3)	
0.2	
(1.3)	
7.9	
(0.9)	
9.1	
(1.3)	
1.2	
(1.7)	
8.1	
(0.6)	
8.4	
(1.0)	
0.3	
(1.0)	
0.1901	 0.2988	 0.1215	
Proportion	with	
≥9%	
10.6	
(1.5)	
10.3	
(1.9)	
-0.3	
(1.9)	
10.4	
(1.3)	
10.4	
(1.9)	
0.0	
(1.5)	
10.6	
(1.4)	
10.6	
(2.1)	
0.0	
(1.6)	
0.8249	 0.8220	 0.6727	
Proportion	with	
≥10%	
11.4	
(1.4)	
11.0	
(1.9)	
-0.4	
(2.2)	
11.3	
(1.3)	
11.3	
(1.8)	
0.0		
(1.5)	
11.6	
(1.1)	
11.9	
(1.8)	
0.3		
(2.0)	
0.8350	 0.3223	 0.5495	
HbA1c	by	
Weight	
Status	at	
Baseline	
Mean	(SD)	
Underweight		
(BMI:	<	5th	
Percentile)	
8.1	
(N=1;	
SD:NA)	
6.9	
(N=1;	
SD:NA)	
-1.2	
(N=1;	
SD:NA)	
-	 -	 -	 -	 -	 -	 -	 -	 -	
Normal/Healthy	
weight		
(BMI:	5th	to	less	
than	85th	
Percentile)	
10.0	
(1.5)	
10.0	
(2.0)	
0.0	
(1.7)	
10.0	
(1.4)	
10.3	
(1.8)	
0.2	
(1.5)	
9.2	
(1.7)	
9.3	
(1.9)	
0.1	
(1.3)	
0.0209	
^#	
0.0885	 0.7735	
Overweight		
(BMI:	85th	to			
less	than	
95thPercentile)	
10.0	
(1.8)	
9.1	
(1.5)	
-0.9	
(1.9)	
9.3	
(1.0)	
9.1	
(1.0)	
-0.2	
(1.1)	
8.3	
(1.0)	
8.8	
(1.4)	
0.5	
(1.9)	
0.0270	
^	
0.8231	 0.1040	
Obese		
(BMI:	≥	95th	
Percentile)	
9.8	
(1.9)	
9.8	
(1.8)	
0.0	
(1.6)	
10.4	
(3.3)	
11.4	
(2.8)	
1.0	
(2.7)	
9.0	
(1.2)	
9.0	
(2.1)	
0.0	
(1.4)	
0.3335	 0.1272	 0.3076	
Statistically significant (P ≤ 0.05) pairwise comparisons of baseline or change data denoted 
by: * (GRAD1 v. GRAD 2); ^ (GRAD 1 v. Non-GRAD); # (GRAD 2 v. Non-GRAD).  
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Table 8: Reported Interest of GRAD staff for FL3X-GRAD Integration 
Topic Questions 
 
Pediatric 
Endocrinologist  
LISW-CP/AP & 
CDE 
RDCDE RN Care 
Manager 
Interest 1. How interested are you 
in thinking about 
integrating FL3X into 
your clinical area? 
(Scale: Low  1 – 2 – 3 – 
4 – 5 – 6 – 7 – 8 – 9 – 
10 High)  
 
2. Why or why not? 
 
1. 10 
 
2. There is a need 
for improved 
behavioral 
management in 
integration with 
blood sugar 
management and 
this intervention 
provides a 
structured, 
effective 
approach. 
1. 10 
 
2. To continue to 
provide extra 
support to 
struggling 
teens and 
families with 
health and 
emotional 
health 
outcomes. 
1. 10 
 
2. There has been 
success with the 
GRAD program 
with these 
approaches. 
1. 9 
 
2. There will 
be better 
contact 
with 
patients, 
especially 
with 
teenagers 
dealing 
with day-
to-day 
issues. 
Ages 11-
16 teens 
face tough 
issues with 
school, 
parents, 
and 
puberty. 
 
What additional information 
would you need to consider 
before making a commitment 
to try FL3X in your clinical 
area? 
Space utilization, 
available resources, 
personnel needs 
What additional 
demands FL3X will 
have on staff? 
 
What is needed for 
additional tool 
platforms such as 
texting or video 
conferencing 
(texting tool was 
overwhelming in the 
past)? 
 
What are the costs?  
 
What support will be 
provided? 
What is return 
on investment? 
 
Costs to 
implement 
FL3X? 
 
 
Table 9: Logistics, Staffing, and Training for FL3X-GRAD Integration 
Topic Questions 
 
Pediatric 
Endocrinologist  
LISW-CP/AP & 
CDE 
RDCDE RN Care 
Manager 
Logistics of 
Integration 
How would you schedule 
FL3X visits in your center? 
Initially, FL3X 
should be at same 
time as provider visit 
as it is hard for 
participants to miss 
school for a separate 
visit. 
Some visits can be 
combined, and 
some visits can be 
separate because 
NP does not have 
to be present at 
every visit. 
 
Visits should be 
combined when 
patient is seeing 
provider and coach.  
 
Separate visit if 
patient is just 
visiting FL3X coach 
 
Combined visits 
are best as it will 
be easier for 
patients further 
away to have visit. 
FL3X was designed to include 
monthly visits with the coach.  
 
1. How will monthly FL3X 
visits work in your 
clinical setting? 
 
2. Would a different interval 
work better? If so, what 
and why?	
1. Monthly visits 
will be a good 
schedule and 
work well with 
current clinical 
setting. 
1. Monthly 
visits would 
be tough. 
 
2. 4-6 weeks 
might be 
more doable 
with available 
time and 
staff. 
1. Monthly visits 
will work 
well. 
1. Monthly 
visits will be 
good. 
 
(Terri) Would 
monitor blood 
sugar readings and 
text patients every 
day 
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1. What cost issues would 
this model pose for you? 
 
2. How would you resolve 
expected cost issues? 
1. Cost issues 
would include 
funding for 
additional 
personnel and 
time for 
oversight. 
 
2. These issues 
would be 
resolved with a 
grant. 
 
1. For the 
department, 
there will be 
staffing costs. 
There will be 
additional 
costs for 
texting and 
other tools. 
 
N/A 1. Cost issues 
would 
include extra 
personnel for 
monthly 
visits.  
 
Costs that won’t be 
reimbursable include initial 
and ongoing coach training 
and certification.  
 
Do you think you can absorb 
these costs? Why or why not? 
 
Cannot absorb these 
costs unless FL3X 
replaces GRAD. 
In the past, 
education and 
training is usually 
covered. 
Absorbing these 
costs should not be 
an issue. 
Medical director 
would resolve 
these issues. 
FL3X Coach Who would be a FL3X coach 
from your center?  
 
Social worker, CDE 
(Linda) 
 
Social worker, 
CDE (Linda) 
 
Social worker, CDE 
(Linda)  
Social worker, 
CDE (Linda)  
Why would the roles you 
selected work for you? 
Already has expertise 
in social work and 
diabetes education as 
CDE 
 
She has 
psychosocial 
background and 
diabetes education. 
 
 
Has psychosocial 
background and 
diabetes education 
knowledge as CDE. 
CDE can look at 
trends in blood 
sugars and make 
suggestions for 
treatment plans. 
 
1. Would FL3X be this 
person’s primary role? 
Why or why not? 
 
2. Would FL3X be in 
addition to their current 
role? Why or why not? 
 
1. No, she has 
other duties in 
clinic.  
 
2. FL3X would be 
in addition to 
current role. 
1. No, she has 
other clinic 
duties.  
 
2. FL3X 
coaching will 
be in addition 
to current 
role. 
1. No, she has 
other clinical 
duties. 
 
2. FL3X would 
be in addition 
to current role. 
1. No, she has 
other clinical 
duties. 
 
2. FL3X would 
be in 
addition to 
current role. 
 
There should be a 
CDE whose 
primary role 
should be FL3X 
coach. 
 
Training and 
Certification 
How much training time is 
reasonable for your setting?  
 
4 hours/month 1-2 hours/week and 
initial intensive 
workshop 
1 hour/week Initial training 
should be over a 
day 
 
Training over time 
should be 2 
hours/month for 
education and 
feedback. 
 
What thoughts to you have 
about the ideal way to provide 
FL3X training in your clinical 
setting? 
 
Can accommodate all 
components of 
training depending on 
coach’s preference. 
Initial work shop 
would be ideal 
with roughly 6/7 
hours over several 
days. Can squeeze 
in time for training 
and feedback over 
time. 
 
N/A Coach should take 
a day for training 
and work in 2 
hours/month into 
schedule. 
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Table 10: Miscellaneous considerations and General Feedback from GRAD staff for FL3X-
GRAD Integration 
Topic Questions 
 
Pediatric 
Endocrinologist  
LISW-CP/AP & 
CDE 
RDCDE RN Care 
Manager 
Miscellaneous What barriers could get in the 
way of implementing FL3X? 
 
Barriers include 
impact on patient 
flow, provider time, 
and space utilization. 
Barriers include 
staffing and 
changes in 
department 
management over 
time.  
 
If FL3X is offered 
just one day a week 
(like GRAD), there 
will be less issues. 
 
Barriers include 
timing of visits and 
co-inciding visits 
with provider 
availability. 
Barriers include 
cost and 
personnel 
issues. 
In most situations, the teen 
decides what will be shared with 
the parent, and the teen and 
parent decide what will be 
shared with their usual care 
team.  
 
How would this work in your 
setting? 
 
It would work well as 
this is how GRAD 
currently works – no 
barriers with this. 
Supports this 
method and team 
should support too. 
This method will 
work fine. However, 
serious 
allegations/situations 
would have to be 
shared. 
Currently, 
GRAD asks 
permission to 
talk separately 
with child and 
with parent. So 
this method will 
work well and is 
necessary 
because there is 
usually conflict 
between parents 
and teens. 
 
How much buy-in would you 
expect from your team? 
 
100% buy-in. All 
providers are excited 
about FL3X. 
There will be great 
buy-in and team is 
open to 
intervention. 
All of the team will 
be on-board. 
The team will 
love it.  
How much buy-in would you 
expect from your teen patients 
and their parents? 
 
Patients interested in 
program like FL3X 
(like patients currently 
in GRAD) will have 
100% buy-in. 
 
General patients that 
are eligible will have 
around 50% buy-in. 
This can be improved 
with provider 
suggestion. 
There would be 
limited buy-in from 
general population. 
 
High buy-in from 
patients currently in 
GRAD.  
 
If after-school hours 
are offered, there 
should be more 
buy-in. 
 
Participants in 
GRAD will have the 
most buy-in. 
 
Some of the general 
patients will buy in. 
Most parents 
will want this 
help. 
 
Most patients 
will be 
interested. 
General 
Feedback 
Comments and Feedback Excited. The 
experience with 
GRAD will help 
transition to FL3X. 
 
Providers should 
help to prepare 
eligible patients for 
FL3X.  
Eligible patients 
should be screened 
for appropriate 
referrals to make 
sure patients are a 
good fit for FL3X. 
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APPENCIES 
Appendix 1: Key differences in Program Design of GRAD 1, GRAD 2, and FL3X 
 GRAD 1 GRAD 2 FL3X 
Eligibility  Age 7-19 years  
 
7 – 19 years, but generally 
recommend age is 11+ years 
13-16 years 
 
Baseline 
HbA1c 
None None 8–13% 
Duration of 
T1D 
None None T1D ≥1 year 
Recruitment 
Method 
Identified by their primary 
diabetes care provider (MD or 
NP) as struggling with poor 
diabetes control and/or poor 
coping skills in Greenville 
Hospital System 
Identified by their primary 
diabetes care provider (MD or 
NP) as struggling with poor 
diabetes control and/or poor 
coping skills in Greenville 
Hospital System 
Identified via medical records 
and recruited via their 
clinicians and by mail and 
telephone calls 
 
Other Criteria Greenville Health System 
 
Greenville Health System 
 
• Patients at either the 
Barbara Davis Center 
for Childhood Diabetes 
(Denver, CO) or 
Cincinnati Children’s 
Hospital and Medical 
Center pediatric 
endocrinology clinic 
• Literacy in English 
• At least 1 primary 
caregiver 
• Excluded if pregnant or 
if had concurrent 
conditions that 
precluded participation 
Interventionists 
and Content of 
Program Visits 
Staff • 1-2 Pediatric Nurse 
Practitioners (PNP) 
• Licensed Clinical Social 
Worker (LCSW) 
 
• 1 Pediatric Nurse 
Practitioner (PNP) 
• Licensed Clinical Social 
Worker/CDE (LCSW/CDE) 
 
FL3X Coaches trained by 
highly experienced, certified 
MI trainer (RN, RD, NR, …) 
Visit Content • PNP:  
o Diabetes 
Education  
o Office visit 
• LCSW:  
o MI guided goal 
setting 
• Parents may or may not 
be present 
• PNP:  
o Office visit 
• LCSW/CDE:  
o Diabetes Education  
o MI guided goal 
setting 
• Parents may or may not be 
present 
 
• FL3X Coach  
o MI guided goal 
setting 
o BRIGHT Ideas 
problem-solving 
skills training 
o Behavioral family 
systems therapy 
o Diabetes toolbox 
o Participants 
allowed to use 
phone to create 
reminders for 
diabetes 
management 
• Parents are present and 
involved in some 
coaching sessions with 
children 
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Frequency of Visits Every 4-8 weeks for follow up 
after initial visit 
Every 4-8 weeks for follow up 
after initial visit 
• “FL3X-Basic” – initial 3 
month session 
o 4 sessions (40-60 
min) 
o Then assigned to 
either “FL3X-
Check-in” or 
“FL3X-Regular” 
• “FL3X- Check-in” 
o ~15 min “touch 
base” outreach 
o Monthly (Months 
4-18) 
• “FL3X- Regular” 
o 40-60 min in 
person sessions 
o Monthly (Months 
4-18) 
 
Outcome Measures 
 
Increase in HbA1c 6 months 
prior GRAD vs. last GRAD 
visit vs. 6 months post GRAD 
completion 
 
None • The primary outcome will 
be HbA1c as a measure of 
average glycemia over the 
prior 6-8 weeks  
• Secondary outcomes 
derived from CGM data 
will include number of 
times per day with 
hypoglycemia (≤70 
mg/dl, ≤60 mg/dl, ≤50 
mg/dl), total time spent in 
hypoglycemia per day 
based on area under the 
curve summed across 
each occasion, and 
percent of days monitored 
in which criteria were met 
at least one time)  
 
Fidelity None None All full-length intervention 
sessions will be audio-taped.  
 
1) assessment of adherence to 
MI principles using the 
Motivational Interviewing 
Treatment Integrity (MITI) 
system; and  
2) review of content fidelity 
using a content checklist. 
Throughout the intervention, 
the first 2 of each session type 
in FL3X Basic (i.e., session 1, 
2, 3, 4) by each coach and a 
random 10% sample of all 
sessions thereafter for each 
coach, will be reviewed with 
feedback to all coaches 
provided in a timely fashion. 
GRAD 1 program design data retrieved from GRAD Manuscript.15 GRAD 2 program data 
retrieved from PNP in on-going GRAD program. FL3X program data obtained from FL3X 
Study Protocol.12 
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Appendix 3: Scheduling and clinic capacity considerations introduced by each integration 
approach 
 
 
 
Scheduling and clinic capacity considerations as compared to the original GRAD program 
Team’s patient capacity Training & 
certification time 
Capacity due to Infrastructure 
FL3X in parallel 
with usual 
diabetes care (as 
FL3X currently 
operates) 
• Lower rate of patient visits 
may be accommodated by the 
schedules of provider and 
FL3X coach (after training) 
due to more frequent, longer 
FL3X visits 
• Training will 
take up time 
from provider 
and coach 
schedules and 
will slow 
clinic flow 
temporarily 
• Lower rate of patient visits may be 
accommodated as physical space is limited by 
separate visit for FL3X coach 
FL3X is usual 
diabetes care  
(all clinic 
patients receive 
FL3X care) 
• Much lower rate of patient 
visits may be accommodated 
by the schedules of FL3X 
coaches especially if no new 
coaches are hired 
• Much lower rate of patient visits may be 
accommodated as physical space is limited by 
separate visit for FL3X visit for all patients  
• Lower rate of patient visits may be 
accommodated if another coach is hired for 
FL3X visits in the same space 
FL3X With 
Office Visit 
Model 
(FL3X coach 
during provider 
visits) 
• Lower rate of patient visits 
may be accommodated with 
FL3X + office visits 
combined (after training) due 
to more frequent, longer 
FL3X + office visits 
• Lower rate of patient visits may be 
accommodated with FL3X + office visits 
combined due to more frequent, longer FL3X + 
visits  
 
 
  
Integration 
Approach 
Financial considerations of integration approaches compared to the original GRAD program 
Training & 
certification 
Provider and coach services Infrastructure Other 
FL3X in 
parallel with 
usual diabetes 
care (as FL3X 
currently 
operates) 
• Funding for 
GRAD clinical 
social workers or 
primary diabetes 
care provider to 
be trained in MI 
as coaches in 
FL3X 
• Additional 
funding for 
training in FL3X 
content (BRIGHT 
Ideas problem-
solving skills 
training, 
behavioral family 
systems therapy, 
diabetes toolbox) 
 
 
• Cost for the longer, 
more frequent FL3X 
visits  
 
 
• Cost of physical space 
used for additional 
FL3X visit in addition 
to provider visit 
• Cost of physical space 
used for longer, more 
frequent FL3X visits 
• Cost of using EHR to 
access and record 
separate visit data 
• Cost for providing 
FL3X content 
including education 
materials/booklets/ 
toolboxes 
• Cost of recording 
and monitoring visits 
for fidelity 
• Costs of analyzing 
program data for 
performance and 
program efficacy 
review 
 
FL3X is usual 
diabetes care  
(all clinic 
patients 
receive FL3X 
care) 
• Cost for all participants 
requiring FL3X visits 
• Cost for the longer, 
more frequent FL3X 
visits  
• Potential need of hiring 
another clinical social 
worker for FL3X visits 
 
• Cost of physical space 
used for additional 
participants  
• Cost of physical space 
used for longer, more 
frequent FL3X visits 
per participant 
• Cost of using EHR to 
access and record 
separate visit data 
FL3X With 
Office Visit 
Model 
(FL3X coach 
during 
provider 
visits) 
• Cost for longer visit 
from combining FL3X 
w/ office visit 
• Cost for more frequent 
FL3X + office visits  
• Cost of physical space 
used for longer, more 
frequent FL3X + office 
visits 
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Appendix 5: Participant Considerations introduced by each integration approach 
 
  
Integration 
Approach 
Team-based care considerations upon integration of FL3X 
Coach & provider 
interactions 
Adoption of new FL3X 
approaches 
Accountability 
FL3X in parallel 
with usual 
diabetes care (as 
FL3X currently 
operates) 
• Social workers 
trained as FL3X 
coaches may be 
unaccustomed to 
conducting visit 
without simultaneous 
provider care 
 
• GRAD team resistance to 
learning and applying FL3X 
approach 
• Difficulty in attributing outcomes of 
former GRAD participants outcomes to 
FL3X visits, prior GRAD visits or both 
FL3X is usual 
diabetes care  
(all clinic 
patients receive 
FL3X care) 
FL3X With 
Office Visit 
Model 
(FL3X coach 
during provider 
visits) 
• FL3X approach may 
be affected by 
simultaneous provider 
care 
  
Integration 
Approach 
Participant considerations upon integration of FL3X 
Eligibility Patient 
time/schedule 
Costs Service Overlap 
FL3X in 
parallel with 
usual diabetes 
care (as FL3X 
currently 
operates) 
• Adopting FL3X 
eligibility criteria 
may discharge 
current participants in 
GRAD program  
• Adopting FL3X 
eligibility criteria 
may also recruit more 
participants than the 
clinic can currently 
take 
• Participants may not be 
able to accommodate 
separate visit for FL3X 
coach in addition to 
provider visit 
• Participants may not be 
able to accommodate 
increased length and 
frequency of visits for 
FL3X 
• Participants may not be 
able to accommodate 
increased length and 
frequency of visits for 
FL3X 
• Participants may 
not be able to 
accommodate 
travel costs for 
separate visits to 
FL3X coach and 
provider 
• Participants may feel 
that some FL3X 
content is overlapping 
with prior GRAD visits  
FL3X is usual 
diabetes care  
(all clinic 
patients 
receive FL3X 
care) 
• Patients who have 
adequate glycemic 
control may not need 
or benefit from FL3X 
• Participants may 
not be able to 
accommodate 
travel costs for 
separate FL3X 
visit and GRAD 
visit 
 
FL3X With 
Office Visit 
Model 
(FL3X coach 
during 
provider 
visits) 
• Adopting FL3X 
eligibility criteria 
may discharge 
current participants in 
GRAD program 
• Adopting FL3X 
eligibility criteria 
may also recruit more 
participants than the 
clinic 
• Participants may not be 
able to accommodate 
increased length and 
frequency of visits for 
FL3X + office visits  
  
